Acura Pharmaceuticals amends loan schedule under secured promissory note with Abuse Deterrent Pharma, lifting aggregated principal to $11.29 million

• Acura Pharmaceuticals amended the loan schedule to its secured promissory note with Abuse Deterrent Pharma dated Nov. 10, 2022.
• The original principal was $2,319,279, with additional loans lifting aggregated principal to $11,294,279 as of Oct. 2, 2026.
• The schedule shows $7,075,000 of additional loans dated Dec. 22, 2022 through Dec. 31, 2025.
• Incremental borrowings in 2026 included $100,000 tranches, with $200,000 draws in June, July, and August.
• The amended schedule was signed Oct. 6, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acura Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-114055), on October 06, 2026, and is solely responsible for the information contained therein.